Cargando…
A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus
BACKGROUND: The treatment strategy for metastatic lesions of primary malignant melanoma of the esophagus (PMME) is currently determined on a case-by-case basis, based on the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma. The NCCN guidelines state that resection shoul...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636353/ https://www.ncbi.nlm.nih.gov/pubmed/36333558 http://dx.doi.org/10.1186/s40792-022-01561-z |
_version_ | 1784824925191667712 |
---|---|
author | Hanada, Keita Tsunoda, Shigeru Nomura, Motoo Fujimura, Shintaro Yutaka, Yojiro Nishigori, Tatsuto Hisamori, Shigeo Maekewa, Hisatsugu Hoshino, Nobuaki Itami, Atsushi Tanaka, Eiji Obama, Kazutaka |
author_facet | Hanada, Keita Tsunoda, Shigeru Nomura, Motoo Fujimura, Shintaro Yutaka, Yojiro Nishigori, Tatsuto Hisamori, Shigeo Maekewa, Hisatsugu Hoshino, Nobuaki Itami, Atsushi Tanaka, Eiji Obama, Kazutaka |
author_sort | Hanada, Keita |
collection | PubMed |
description | BACKGROUND: The treatment strategy for metastatic lesions of primary malignant melanoma of the esophagus (PMME) is currently determined on a case-by-case basis, based on the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma. The NCCN guidelines state that resection should be considered in patients with resectable metastatic recurrence. Herein, we report a case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for the metastatic recurrence of PMME. CASE PRESENTATION: A 65-year-old female patient with PMME underwent thoracoscopic subtotal esophagectomy, gastric tube reconstruction via the posterior mediastinal route, and cervical esophagogastric anastomosis. Histopathological examination of the resected specimen revealed that the tumor was PMME with tumor invasion into the muscularis propria and no lymph node metastasis. At the age of 68 years, she developed intestinal invagination due to jejunal metastasis of malignant melanoma and underwent resection of the jejunum. Histopathological examination of the resected specimen revealed two metastases of malignant melanoma in the jejunum and one metastasis to the mesenteric lymph node. At the age of 75 years, a recurrence of malignant melanoma was found in the cervical esophagus. She underwent thoracoscopic mobilization of the gastric tube and esophagus followed by cervical esophagectomy and reconstruction with a free jejunum flap. She received 24 courses of nivolumab therapy for 1 year as a postoperative adjuvant therapy. Subsequently, at the age of 78 years, an enlarged left cervical lymph node and a mass in the right lower lobe of the lung were found. She underwent left cervical lymph node dissection and thoracoscopic wedge resection of the right lung. Histopathological examination of the resected specimens revealed that both tumors were metastases of malignant melanoma. At age 79 years, she received eight courses of nivolumab therapy as a second postoperative adjuvant therapy, with no sign of recurrence in a 9-month follow-up period after the third metastasectomy. CONCLUSION: In cases of metastatic recurrence of PMME, aggressive resection of oligometastasis with postoperative adjuvant nivolumab therapy may result in long-term survival. |
format | Online Article Text |
id | pubmed-9636353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-96363532022-11-06 A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus Hanada, Keita Tsunoda, Shigeru Nomura, Motoo Fujimura, Shintaro Yutaka, Yojiro Nishigori, Tatsuto Hisamori, Shigeo Maekewa, Hisatsugu Hoshino, Nobuaki Itami, Atsushi Tanaka, Eiji Obama, Kazutaka Surg Case Rep Case Report BACKGROUND: The treatment strategy for metastatic lesions of primary malignant melanoma of the esophagus (PMME) is currently determined on a case-by-case basis, based on the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma. The NCCN guidelines state that resection should be considered in patients with resectable metastatic recurrence. Herein, we report a case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for the metastatic recurrence of PMME. CASE PRESENTATION: A 65-year-old female patient with PMME underwent thoracoscopic subtotal esophagectomy, gastric tube reconstruction via the posterior mediastinal route, and cervical esophagogastric anastomosis. Histopathological examination of the resected specimen revealed that the tumor was PMME with tumor invasion into the muscularis propria and no lymph node metastasis. At the age of 68 years, she developed intestinal invagination due to jejunal metastasis of malignant melanoma and underwent resection of the jejunum. Histopathological examination of the resected specimen revealed two metastases of malignant melanoma in the jejunum and one metastasis to the mesenteric lymph node. At the age of 75 years, a recurrence of malignant melanoma was found in the cervical esophagus. She underwent thoracoscopic mobilization of the gastric tube and esophagus followed by cervical esophagectomy and reconstruction with a free jejunum flap. She received 24 courses of nivolumab therapy for 1 year as a postoperative adjuvant therapy. Subsequently, at the age of 78 years, an enlarged left cervical lymph node and a mass in the right lower lobe of the lung were found. She underwent left cervical lymph node dissection and thoracoscopic wedge resection of the right lung. Histopathological examination of the resected specimens revealed that both tumors were metastases of malignant melanoma. At age 79 years, she received eight courses of nivolumab therapy as a second postoperative adjuvant therapy, with no sign of recurrence in a 9-month follow-up period after the third metastasectomy. CONCLUSION: In cases of metastatic recurrence of PMME, aggressive resection of oligometastasis with postoperative adjuvant nivolumab therapy may result in long-term survival. Springer Berlin Heidelberg 2022-11-04 /pmc/articles/PMC9636353/ /pubmed/36333558 http://dx.doi.org/10.1186/s40792-022-01561-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Case Report Hanada, Keita Tsunoda, Shigeru Nomura, Motoo Fujimura, Shintaro Yutaka, Yojiro Nishigori, Tatsuto Hisamori, Shigeo Maekewa, Hisatsugu Hoshino, Nobuaki Itami, Atsushi Tanaka, Eiji Obama, Kazutaka A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus |
title | A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus |
title_full | A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus |
title_fullStr | A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus |
title_full_unstemmed | A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus |
title_short | A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus |
title_sort | case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636353/ https://www.ncbi.nlm.nih.gov/pubmed/36333558 http://dx.doi.org/10.1186/s40792-022-01561-z |
work_keys_str_mv | AT hanadakeita acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT tsunodashigeru acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT nomuramotoo acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT fujimurashintaro acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT yutakayojiro acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT nishigoritatsuto acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT hisamorishigeo acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT maekewahisatsugu acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT hoshinonobuaki acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT itamiatsushi acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT tanakaeiji acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT obamakazutaka acaseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT hanadakeita caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT tsunodashigeru caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT nomuramotoo caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT fujimurashintaro caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT yutakayojiro caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT nishigoritatsuto caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT hisamorishigeo caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT maekewahisatsugu caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT hoshinonobuaki caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT itamiatsushi caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT tanakaeiji caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus AT obamakazutaka caseoflongtermsurvivaltreatedwiththreemetastasectomiesandtwosubsequentadjuvantnivolumabtherapiesforrecurrentmalignantmelanomaoftheesophagus |